Literature DB >> 2706316

The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation.

K S Patrick1, A B Straughn, E J Jarvi, G R Breese, M C Meyer.   

Abstract

A crossover study in 18 subjects evaluated the plasma concentration-time profile of two different 20 mg sustained-release (SR) methylphenidate (MPH) tablets administered before breakfast, compared to a 10 mg immediate-release (IR) tablet administered before breakfast and again 5 h later, before lunch. Plasma MPH concentrations were determined using a sensitive and precise gas chromatography-mass spectrometry method, incorporating a deuterated internal standard. The mean peak MPH concentration was 6.4 ng ml-1 for the IR product versus 4.6 ng ml-1 and 4.8 ng ml-1 for the two SR formulations. Peak concentrations occurred at 3.3 h after dosing with the SR products, compared to 1.5 h after the first dose of the IR product. The extent of absorption for the three products, as determined from areas under the plasma concentration-time curves, were within 5 per cent of each other. There was no significant difference in rate or extent of absorption between the two SR formulations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706316     DOI: 10.1002/bdd.2510100206

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  12 in total

1.  Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability.

Authors:  M C Meyer; A B Straughn; E J Jarvi; K S Patrick; F R Pelsor; R L Williams; R Patnaik; M L Chen; V P Shah
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

2.  The bioinequivalence of carbamazepine tablets with a history of clinical failures.

Authors:  M C Meyer; A B Straughn; E J Jarvi; G C Wood; F R Pelsor; V P Shah
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

Review 3.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

Review 4.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Effects of food on the pharmacokinetics of methylphenidate.

Authors:  K K Midha; G McKay; M J Rawson; E D Korchinski; J W Hubbard
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

6.  Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick; C Lindsay DeVane; Linda Pestreich; James Lee; Yanfeng Wang; Rafael Muniz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma.

Authors:  Hao-Jie Zhu; Jun-Sheng Wang; Kennerly S Patrick; Jennifer L Donovan; C Lindsay DeVane; John S Markowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-19       Impact factor: 3.205

8.  Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.

Authors:  N R Srinivas; J W Hubbard; E D Korchinski; K K Midha
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

Review 9.  Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.

Authors:  Kennerly S Patrick; Timothy R Corbin; Cristina E Murphy
Journal:  J Pharm Sci       Date:  2014-10-09       Impact factor: 3.534

10.  Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; Arthur B Straughn; Owen T Reeves; Hilary Bernstein; Jian Shi; Heather J Johnson; Joshua M Knight; Aaron T Smith; Robert J Malcolm; John S Markowitz
Journal:  J Clin Psychopharmacol       Date:  2017-08       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.